<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326102</url>
  </required_header>
  <id_info>
    <org_study_id>107CS-6</org_study_id>
    <nct_id>NCT03326102</nct_id>
  </id_info>
  <brief_title>Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer</brief_title>
  <acronym>OPERA</acronym>
  <official_title>A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daehwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daehwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of
      DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients
      with Recurrent or Metastatic Breast Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be assigned to DHP107 or IV paclitaxel in a ratio of 2:1 (n=48 to DHP107 and n=24 to IV paclitaxel)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>Every 8 weeks upto 18 months from randomization date</time_frame>
    <description>ORR is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>PFS is defined as the time from date of randomization until the date of first documented progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to 36 months from FPI</time_frame>
    <description>OS is defined as the time from the date of inclusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure(TTF)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>DOR is the time between the initial response to therapy and subsequent disease progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>Up to 18 months from randomization date</time_frame>
    <description>DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QoL)</measure>
    <time_frame>after randomization(C1D1), D1 of every 3rd cycle(each cycle consists of 28 days) up to 18 months</time_frame>
    <description>Evaluate changes compared to baseline using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>on Day 1 of Cycle 1(each cycle consists of 28days) at predose, 1, 2, 3, 4, 6 and 10 hrs post dose (before the 2nd dose on Day 1) and on Day 8 of Cycle 1 at predose (before the 1st dose on Day 8)</time_frame>
    <description>Time to reach observed maximum concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>DHP107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.
Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHP107</intervention_name>
    <description>DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days</description>
    <arm_group_label>DHP107</arm_group_label>
    <other_name>Liporaxel®, Oral Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Paclitaxel</intervention_name>
    <description>IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)</description>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <other_name>Taxol Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Subjects with confirmed diagnosis of recurrent or metastatic breast cancer based on
             histopathology examination

          2. Subjects with diagnosis of HER2-negative breast cancer that was confirmed by IHC or in
             situ hybridization (ISH) assessment of tumor samples

          3. Subjects who have received up to 3 lines of therapy for advanced disease, without
             prior exposure to taxane in the advanced stage setting

          4. Subjects who have a performance status of ≤2 on the Eastern Cooperative Oncology Group
             (ECOG) scale.

          5. Subjects who have measurable disease according to the Response Evaluation Criteria in
             Solid Tumors Version 1.1 (RECIST version 1.1).

        Key Exclusion Criteria:

          1. Subjects who have received prior taxane therapy in the metastatic setting

          2. Subjects whose adjuvant or neoadjuvant treatment for early stage breast cancer was
             completed within 6 months prior to entry into the study.

          3. Subjects with neuropathy grade ≥2 based on CTCAE v4.03 at the time of study entry

          4. Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at
             the time of screening.

          5. Subjects who have received any investigational drugs or devices within 4 weeks before
             the first day of study treatment (C1D1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope Rugo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Weng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anne Arundel Health System Research Institute (AAHS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neelima Vidula, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital (MGH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Brufsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center (UPMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Pluard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Luke's Cancer Institute(SLCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Priyanka Sharma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center(KUMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Skelton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boca Raton Regional Hospital (BRRH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Caradonna, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASCLEPES Research Center(ARC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro-Minnesota Community Oncology Research Consortium (MMCORC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Gordon, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Center of Medical Research(MCMR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghassan Aljazayrly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Research Institute (CRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ellerton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nevada Cancer Research Foundation (NCRF)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hope Rugo, M.D.</last_name>
    <phone>415-353-7070</phone>
    <email>Hope.Rugo@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Research Institute (CRI)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghassan Aljazayrly, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rugo Hope, M.D.</last_name>
      <phone>415-353-7070</phone>
      <email>Hope.Rugo@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Melisko, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital (BRRH)</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Center(ARC)</name>
      <address>
        <city>Weeki Wachee</city>
        <state>Florida</state>
        <zip>34607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Caradonna, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute(SLCI)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Pluard, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center(KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Sharma, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System Research Institute (AAHS)</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital(MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidula Neelima, M.D.</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Center of Medical Research(MCMR)</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Gordon, D.O.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota Community Oncology Research Consortium (MMCORC)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Ji, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation (NCRF)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ellerton, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>DHP107</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Liporaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

